Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

FDA may have to exit its drug review comfort zone and accept more trials outside the classic double-blind, placebo-controlled realm to promote more orphan drug development, industry and advocacy organizations told the agency